IDXX 153.00 Idexx Laboratories $IDXX Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 12:15 PM

IDXX 153.00 Idexx Laboratories $IDXX Hit a 52 week high of 153.89 Closing the day 09:44 at 153.00 +0.12 +0.08% With a day low of 152.75 and a total volume of 13,002.

IDXX Recent Posts: http://investorshangout.com/IDEXX-Laboratorie...DXX-54421/

IDXX Idexx Laboratories Recent Headline News

Uptrend Call Working As Idexx Laboratories Stock Rises 24.1% (IDXX)
Comtex SmarTrend(R) - Wed Nov 12, 9:56AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 3 weeks, Idexx Laboratories has returned 24.07% as of today's recent price of $152.00.
IDXX: 152.54 (-0.34)

Trade-Ideas: Idexx Laboratories (IDXX) Is Today's Strong And Under The Radar Stock
at The Street - Tue Nov 11, 9:42AM CST
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 152.54 (-0.34)

SmarTrend Watching for Potential Pullback in Shares of Idexx Laboratories After 1.39% Gain
Comtex SmarTrend(R) - Mon Nov 10, 5:17PM CST
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $144.18 to a high of $147.67. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $146.00 on volume of 560,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 152.54 (-0.34)

Idexx Laboratories Earnings Hindsight: Up 7.4% in Last 17 Days (IDXX)
Comtex SmarTrend(R) - Mon Nov 10, 1:31PM CST
17 days ago, on October 24th, 2014, Idexx Laboratories (NASDAQ:IDXX) reported its earnings. Analysts, on average, expected earnings of $0.86 per share on sales of $371.3 million. Idexx Laboratories actually reported earnings of $1.05 per share on sales of $383.5 million, beating EPS estimates by $0.19 and beating revenue estimates by $12.2 million. Since the company's report, shares of Idexx Laboratories have risen from $135.20 to $145.16, representing a gain of 7.4% in the past 17 days.
IDXX: 152.54 (-0.34)

Idexx Laboratories Has Returned 17.5% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Nov 05, 9:25AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 2 weeks, Idexx Laboratories has returned 17.52% as of today's recent price of $143.98.
IDXX: 152.54 (-0.34)

Comparing America's 3 Largest Diagnostic Substances Companies
Joseph Cafariello - at Seeking Alpha - Mon Nov 03, 12:03PM CST

QDEL: 28.28 (-0.11), NEOG: 44.22 (-0.38), IDXX: 152.54 (-0.34)

Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 188.04 (+1.17), GE: 26.48 (-0.04), BMRN: 87.21 (+0.26), IDXX: 152.54 (-0.34), GSK: 45.70 (+0.08), NVS: 94.40 (+1.74)

IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:57AM CDT
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue?
IDXX: 152.54 (-0.34)

IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.44 (+0.02), EW: 124.17 (+1.22), IDXX: 152.54 (-0.34), ANGO: 16.89 (-0.09)

Today's Strong And Under The Radar Stock Is Idexx Laboratories (IDXX)
at The Street - Tue Oct 28, 8:51AM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 152.54 (-0.34)

IDEXX Laboratories, Inc. Is as Fit as a Butcher's Dog
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 24, 6:56PM CDT
Shares of IDEXX Laboratories jumped 7% today after reporting a solid third quarter, raising 2014 guidance, and issuing 2015 guidance that looks even better. The stock of the animal health-test provider soared to a 52-week and all-time high. ...
IDXX: 152.54 (-0.34)

Idexx Laboratories Set to Possibly Pullback After Yesterday's Rally of 7.00%
Comtex SmarTrend(R) - Fri Oct 24, 4:12PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $130.06 to a high of $140.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $126.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 152.54 (-0.34)

IDEXX Laboratories' (IDXX) CEO Jon Ayers on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 24, 1:02PM CDT

IDXX: 152.54 (-0.34)

Idexx Q3 income up 14%
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 10:00AM CDT

IDXX: 152.54 (-0.34)

Idexx beats Street 3Q forecasts
Automated Insights - Fri Oct 24, 6:27AM CDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported net income of $52.1 million in its third quarter.
IDXX: 152.54 (-0.34)

IDEXX Laboratories beats by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 6:07AM CDT

IDXX: 152.54 (-0.34)

IDEXX Laboratories Announces Third Quarter Results
PR Newswire - Fri Oct 24, 6:00AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that revenues for the third quarter of 2014 increased 13% versus the prior year period to $384 million. Organic revenue growth1 for the third quarter of 2014 versus the prior year period was also 13%, or 11% normalized for changes in distributor inventory2. Earnings per diluted share ("EPS"

for the quarter ended September 30, 2014 increased 21% from the prior year period to $1.03. Adjusted EPS3 for the quarter was $1.05.
IDXX: 152.54 (-0.34)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 4:30PM CDT

WYN: 79.81 (-0.26), SFE: 19.51 (-0.10), F: 15.01 (+0.43), OCR: 69.32 (+0.45), B: 37.44 (+0.09), SXC: 22.89 (-0.02), VTR: 69.14 (+0.79), UPS: 108.08 (-0.54), DLPH: 70.64 (+0.19), CHH: 53.09 (-0.02), LYB: 87.78 (-0.81), COG: 32.72 (-0.75), SHPG: 202.02 (+1.51), TCB: 15.95 (-0.07), AVY: 48.17 (+0.07), AAN: 27.47 (-0.13), MGLN: 61.35 (-0.28), STT: 76.09 (-1.36), FNFG: 7.77 (-0.01), IMGN: 10.10 (-0.02), EDU: 21.99 (+0.18), BMY: 57.83 (-0.78), DTE: 80.66 (-0.24), LEA: 93.05 (+0.62), MCO: 100.38 (+0.30), FLIR: 32.73 (-0.25), IMS: 24.69 (-0.01), LPNT: 64.20 (-0.36), ERIC: 12.06 (+0.25), PG: 89.26 (-0.22), IDXX: 152.54 (-0.34), WBC: 100.97 (-1.27), NDAQ: 43.81 (-0.22), CL: 68.65 (-0.05)

Oracle Enterprise Manager Enables Seamless IT Management and Visibility for IDEXX Laboratories
Marketwired - Wed Oct 15, 7:04AM CDT
Oracle (NYSE: ORCL)
IDXX: 152.54 (-0.34), ORCL: 40.50 (+0.36)

IDEXX Laboratories to Release 2014 Third Quarter Financial Results
PR Newswire - Tue Oct 14, 12:45PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2014 third quarter financial results for Friday, October 24, 2014 at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
IDXX: 152.54 (-0.34)

IDEXX Laboratories Inc (IDXX) Stock Research Links

IDXX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Princess Cruises Launches New Era at Celebration Key

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Investors Gear Up for Lennar Class Action Lawsuit

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...